Popular weight-loss drugs linked to higher anaesthesia risk
Semaglutide, a glucagon-like peptide-1 receptor agonist, or GLP-1 RA, have transformed the treatment of type 2 diabetes and obesity.
Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), has revolutionized the treatment of type 2 diabetes and obesity by controlling blood glucose, reducing appetite, and promoting weight loss. However, recent UK research indicates these drugs may pose a safety risk for patients undergoing anesthesia. A substantial study involving over 47,000 patients revealed that those taking GLP-1 RAs were approximately 11 times more likely to experience regurgitation or pulmonary aspiration during anesthesia compared to non-users.
The actual risk was still minimal, with complications occurring in 1.41% of GLP-1 RA users versus 0.12% of non-users. Glucagon-like peptide-1 receptor agonists slow stomach emptying, meaning patients might retain food or fluid in the stomach even after following fasting instructions, increasing the likelihood of stomach contents entering the lungs.
While the researchers cannot definitively attribute the increased risk to the drugs themselves, as obesity and diabetes may also play a role, the crucial takeaway is that patients on semaglutide, tirzepatide, or similar medications should inform their surgeon and anesthetist before any procedure requiring anesthesia.
Written by urgent.news from Daily Star BD Health's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
